Accelerate Brain Cancer Cure (ABC2) and the Tug McGraw Foundation Unite to Address
Quality of Life for Patients with Brain Cancer

Accelerate Brain Cancer Cure and the Tug McGraw Foundation have jointly awarded a 2006 research grant to Terri S. Armstrong, DSN, APRN, BC, Neuro-Oncology, M.D. Anderson Cancer Center to support her work on, "Gauging Impact of Treatment on Symptoms, Health Related Quality of Life and Neurocognitive Function in Patients with Primary Brain Tumors." Armstrong is the recipient of the first grant awarded jointly by these two non-profit foundations. This award targets quality of life and support of care in patients with brain cancer and is the result of a natural collaboration, combining ABC2's dedication to accelerating therapies leading to a cure for brain cancer and the Tug McGraw Foundation's commitment to enhancing the quality of life for children and adults with brain tumors and their families.

About the Research
Typically, clinical trials measure efficacy in terms of response or survival. Although recent clinical trials have demonstrated improved survival with novel therapeutic regimens, patients diagnosed with glioblastoma (GBM) face unique obstacles. Management of these patients presents new challenges — partly due to the complexity of the disease and treatment — and the effect of the disease and treatment for the patients is rarely assessed.

This research grant will build upon the current work of the Radiation Therapy Oncology Group's large international collaborative clinical trial (RTOG 0525) that compares standard radiation and chemotherapy to dose-intense (temozolomide) chemotherapy. RTOG 0525 will evaluate survival between the two treatments. While preliminary studies suggest that the intensive regime is tolerable, there may be important impact on other measures of patient status, such as health related quality of life, symptom burden and neurocognitive function.

In her study, Armstrong aims to look beyond survivability and treatment response to quantify the impact of an increased dose-intensity of temozolomide in the adjuvant phase of treatment on quality of life, symptom burden and neurocognitive function. Armstrong's study holds the potential to establish a new paradigm of therapeutic efficacy whereas the assessment of treatment impact on the patient is combined with traditional measures of treatment efficacy. Prospectively, Armstrong intends to advance the field by establishing a new standard for comprehensive treatment evaluation and will, therefore, support the concept of a meaningful response, incorporating both classic clinical endpoints as well as outcome measures that evaluate patient symptoms and functional status.

The ABC2/Tug McGraw Foundation Grant will support enrollment, testing and analysis of 240 study patients.

About Accelerate Brain Cancer Cure
ABC2 was founded in May 2001 by Dan and Steve Case and their families, along with leading scientists and entrepreneurs. ABC2 aims to raise awareness about brain cancer and help mobilize critical scientific research through research grants and partnerships. ABC2 funds outstanding and novel translational science that is aimed at the discovery of a cure for brain cancer.

Additional information can be found at

About The Tug McGraw Foundation
The Tug McGraw Foundation was established by Tug McGraw in 2003 to raise funds to enhance the quality of life of children and adults with brain tumors and their families by stimulating and facilitating research that addresses the physical, social, emotional, cognitive, and spiritual impact of the disease.

Additional information can be found at